Antisense Therapeutics (ASX: ANP)

Last close As at 05/03/2025

0.07

0.00 (−2.94%)

Market capitalisation

60m

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Latest Insights

Further insights

insight

Healthcare

Healthcare Week 2023

Thematics

thematic

TMT

MediaWatch – What now?

thematic

Industrials

Climate: Creating multi-trillion investment opportunities

thematic

Consumer

ConsumerWatch – Looking for a sign

thematic

Financials

Molten Ventures – executive interviews

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free